Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gullapalli, Sneha, Remon, Jordi, Hendriks, Lizza E L, Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369644/
https://www.ncbi.nlm.nih.gov/pubmed/32764980
http://dx.doi.org/10.2147/OTT.S259308
_version_ 1783560816109289472
author Gullapalli, Sneha
Remon, Jordi
Hendriks, Lizza E L
Lopes, Gilberto
author_facet Gullapalli, Sneha
Remon, Jordi
Hendriks, Lizza E L
Lopes, Gilberto
author_sort Gullapalli, Sneha
collection PubMed
description Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as monotherapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.
format Online
Article
Text
id pubmed-7369644
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73696442020-08-05 Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context Gullapalli, Sneha Remon, Jordi Hendriks, Lizza E L Lopes, Gilberto Onco Targets Ther Review Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as monotherapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients. Dove 2020-07-14 /pmc/articles/PMC7369644/ /pubmed/32764980 http://dx.doi.org/10.2147/OTT.S259308 Text en © 2020 Gullapalli et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Gullapalli, Sneha
Remon, Jordi
Hendriks, Lizza E L
Lopes, Gilberto
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
title Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
title_full Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
title_fullStr Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
title_full_unstemmed Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
title_short Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
title_sort update on targeted therapies for advanced non-small cell lung cancer: durvalumab in context
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369644/
https://www.ncbi.nlm.nih.gov/pubmed/32764980
http://dx.doi.org/10.2147/OTT.S259308
work_keys_str_mv AT gullapallisneha updateontargetedtherapiesforadvancednonsmallcelllungcancerdurvalumabincontext
AT remonjordi updateontargetedtherapiesforadvancednonsmallcelllungcancerdurvalumabincontext
AT hendrikslizzael updateontargetedtherapiesforadvancednonsmallcelllungcancerdurvalumabincontext
AT lopesgilberto updateontargetedtherapiesforadvancednonsmallcelllungcancerdurvalumabincontext

Ejemplares similares